LGND · Ligand Pharmaceuticals Inc

$288.01 -8.27 (-2.79%) At close · Jul 29

Market Cap

$5.94B

20.04M

Share-repurchase activity from the company's own XBRL filings — cash spent buying back common stock per fiscal year and per recent quarter, share counts where the company tagged them, and the buyback program's authorization — paired with the company's at-the-market (ATM) equity offering programs, the dilution side of the same picture. Repurchase amounts come exclusively from tagged SEC data; program figures with no tagged equivalent (untagged authorizations and all ATM figures) are read from the filing's own text and shown only after verification.

Program Authorized

$50,000,000

as of 2024-06-30 · not restated in filings since 2024-08-07

Remaining Authorization

$50,000,000

as of 2024-09-30 · not restated in filings since 2024-11-08

Program Utilization

0.0% $0 used of $50,000,000

Equity Offering (ATM) Programs

Program Established	Capacity	Sold	Remaining	As of	Runs Through	Source
2022-09-30	$100,000,000	$37,400,000	—	2026-02-27	—	10-K , filed 2026-02-27

Cash spent on buybacks by quarter

Cash deployed each quarter. Δ marks quarters derived from the company's cumulative year-to-date disclosures.

Repurchase History

Fiscal Year Ended	Cash Spent	Shares	Avg Price	Source
2025-12-31	$15,000,000	—	—	10-K, filed 2026-02-27
2024-12-31	$0	—	—	10-K, filed 2026-02-27
2023-12-31	$0	—	—	10-K, filed 2026-02-27
2022-12-31	$0	—	—	10-K, filed 2023-02-28
2021-12-31	$0	—	—	10-K, filed 2023-02-28
2020-12-31	$77,998,000	934,079	$83.50	10-K, filed 2023-02-28
2019-12-31	$453,048,000	4,122,133	$109.91	10-K, filed 2022-02-28
2018-12-31	$122,868,000	782,248	$157.07	10-K, filed 2021-02-24
2017-12-31	$1,966,000	14,000	$140.43	10-K, filed 2020-02-27
2016-12-31	$3,901,000	40,500	$96.32	10-K, filed 2019-02-28
2015-12-31	$489,000	6,120	$79.92	10-K, filed 2018-03-01
2014-12-31	$67,954,000	1,253,425	$54.20	10-K, filed 2017-02-28
2013-12-31	$0	—	—	10-K, filed 2016-11-14
2012-12-31	$0	—	—	10-K, filed 2015-02-23
2011-12-31	$55,000	—	—	10-K/A, filed 2014-12-12
2010-12-31	$91,000	—	—	10-K, filed 2013-03-14

Quarter Ended	Cash Spent	Shares	Avg Price	Source
2025-12-31	$0 Δ	—	—	10-K, filed 2026-02-27
2024-12-31	$0 Δ	—	—	10-K, filed 2026-02-27
2021-12-31	$0 Δ	—	—	10-K, filed 2023-02-28
2021-09-30	$0 Δ	—	—	10-Q, filed 2021-11-09
2021-06-30	$0 Δ	—	—	10-Q, filed 2021-08-03
2021-03-31	$0	—	—	10-Q, filed 2021-05-06
2020-12-31	$4,711,000 Δ	—	—	10-K, filed 2023-02-28
2020-09-30	$0 Δ	—	—	10-Q, filed 2021-11-09
2020-06-30	$0 Δ	—	—	10-Q, filed 2021-08-03
2020-03-31	$73,287,000	—	—	10-Q, filed 2021-05-06
2019-12-31	$81,942,000 Δ	—	—	10-K, filed 2022-02-28
2019-09-30	$181,189,000 Δ	—	—	10-Q, filed 2020-11-06

Key facts CIK 886163 CUSIP 53220K504 13F (30d) 117 filings 114 filers Visit website Investor relations